Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 917-931

  Wright, D Hamish ^a   Stone, Julie A ^a   Crumley, Tami M ^a   Wenning, Larissa ^a   Zheng, Wei ^a   Yan, Kerri ^a   Yang, Amy Yifan ^a   Sun, Li ^a   Cilissen, Caroline ^b   Ramael, Steven ^c   Hermanowski Vosatka, Anne ^a   Langdon, Ronald B ^a   Gottesdiener, Keith M ^a   Wagner, John A ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD Europe   (Belgium)

^c SGS Life Science Services   (Belgium)

Author keywords

11 hydroxysteroid dehydrogenase type 1; cortisol; cortisone; metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 [ 1 ( 4 CHLOROPHENYL) 3 FLUOROCYCLOBUTYL] 4,5 DICYCLOPROPYL 4H 1,2,4 TRIAZOLE; CARBON 13; CORTISONE; HYDROCORTISONE; MK 0916; OXIDOREDUCTASE INHIBITOR; PLACEBO; STABLE ISOTOPE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DISORIENTATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOGEUSIA; IC 50; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NIGHTMARE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRASTERONE SULFATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS;

11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1; CORTISOL; CORTISONE; METABOLIC SYNDROME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TRIAZOLES; YOUNG ADULT;

EID: 84888025288     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12131     Document Type: Article

References (24)

1. Wamil M, Seckl JR,. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007; 12: 504-520.
2. Cooper MS, Stewart PM,. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009; 94: 4645-4654.
3. Morton NM,. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010; 316: 154-164.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
5. Seckl JR, Walker BR,. Minireview: 11β-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-1376.
6. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM,. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-866.
7. Chrousos GP,. Is 11 β -hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc Natl Acad Sci U S A 2004; 101: 6329-6330.
8. Thieringer R, Hermanowski-Vosatka A,. Inhibition of 11β-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role? Expert Rev Cardiovasc Ther 2005; 3: 911-924.
9. Gibbs JP, Emery MG, McCaffery I, Smith B, Gibbs MA, Akrami A, Rossi J, Paweletz K, Gastonguay MR, Bautista E, Wang M, Perfetti R, Daniels O,. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11{beta}-HSD1 inhibitor. J Clin Pharmacol 2011; 51: 830-841.
10. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R, INCB13739-202 Principal Investigators. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010; 33: 1516-1522.
11. Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD,. Effects of an 11β-hydroxysteroid dehydrogenase type 1 (HSD1) inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011; 13: 498-504.
12. Shah S, Hermanowski-Vosatka A, Gibson K, Ruck RA, Jia G, Zhang J, Hwang PM, Ryan NW, Langdon RB, Feig PU,. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hyperten 2011; 5: 166-176.
13. Zhu Y, Olson SH, Graham D, Patel G, Hermanowski-Vosatka A, Mundt S, Shah K, Springer M, Thieringer R, Wright S, Xiao J, Zokian H, Dragovic J, Balkovec JM,. Phenylcyclobutyl triazoles as selective inhibitors of 11β- hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett 2008; 18: 3412-3416.
14. Kasuya Y, Ishimaru H, Shibasaki H, Furuta T,. Stable isotope methodology for kinetic studies of interconversion of cortisol and cortisone in a human subject. Steroids 1998; 63: 122-129.
15. Kasuya Y, Yokokawa A, Takayama S, Shibasaki H, Furuta T,. Evaluation of 11β-HSD activities in vivo following oral administration of cortisol-13C4,2H1 to a human subject. Steroids 2003; 68: 167-176.
16. Metropolitan Life Insurance Company. Metropolitan height and weight tables. Stat Bull 1983; 64: 2-9.
17. Sun L, Stenken JA, Brunner JE, Michel KB, Adelsberger JK, Yang AY, Zhao JJ, Musson DG,. An in vivo microdialysis coupled with liquid chromatography/tandem mass spectrometry study of cortisol metabolism in monkey adipose tissue. Anal Biochem 2008; 381: 214-223.
18. Yang AY, Sun L, Musson DG, Zhao JJ,. Determination of M+4 stable isotope labeled cortisone and cortisol in human plasma by microElution solid-phase extraction and liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 233-240.
19. Sun L, Stenken JA, Yang AY, Zhao JJ, Musson DG,. An in vitro microdialysis methodology to study 11β-hydroxysteroid dehydrogenase type 1 enzyme activity in liver microsomes. Anal Biochem 2007; 370: 26-37.
20. Brazzell RK, Mayer PR, Dobbs R, McNamara PJ, Teng RL, Slattery JT,. Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man. Pharm Res 1991; 8: 112-118.
21. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-532.
22. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC,. Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary- adrenal axis: analysis of 11beta-HSD-1-deficient mice. Endocrinology 2001; 142: 114-120.
23. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, MUndt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Stowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R,. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202: 517-527.
24. Harno E, White A,. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis? Trends Endocrinol Metab 2010; 21: 619-627.